- Home
- DNTH vs VCEL Comparison
DNTH vs VCEL Comparison
Compare DNTH & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNTH | VCEL |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | DNTH | VCEL |
|---|---|---|
| Price | $45.90 | $35.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $68.88 | $57.50 |
| AVG Volume (30 Days) | ★ 811.5K | 586.8K |
| Earning Date | 03-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | $3,078,000.00 | ★ $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ N/A | $151.65 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | $13.37 | $29.24 |
| 52 Week High | $46.59 | $63.00 |
Technical Indicators
Market Signals| Indicator | DNTH | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 62.86 | 43.31 |
| Support Level | $42.37 | $35.99 |
| Resistance Level | $46.59 | $39.07 |
| Average True Range (ATR) | 2.79 | 1.76 |
| MACD | 0.67 | -0.14 |
| Stochastic Oscillator | 93.35 | 8.19 |
Price Performance
Historical ComparisonAbout DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.